JP2011102255A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011102255A5 JP2011102255A5 JP2009257281A JP2009257281A JP2011102255A5 JP 2011102255 A5 JP2011102255 A5 JP 2011102255A5 JP 2009257281 A JP2009257281 A JP 2009257281A JP 2009257281 A JP2009257281 A JP 2009257281A JP 2011102255 A5 JP2011102255 A5 JP 2011102255A5
- Authority
- JP
- Japan
- Prior art keywords
- anticancer agent
- akr1c
- anticancer
- fluorouracil
- cisplatin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002246 antineoplastic agent Substances 0.000 claims description 28
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 16
- 229960002949 fluorouracil Drugs 0.000 claims description 16
- 229960004316 cisplatin Drugs 0.000 claims description 9
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 9
- 239000003623 enhancer Substances 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 7
- 239000003112 inhibitor Substances 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 229940041181 antineoplastic drug Drugs 0.000 claims 6
- 230000000857 drug effect Effects 0.000 claims 5
- 102000005602 Aldo-Keto Reductases Human genes 0.000 claims 4
- 108010084469 Aldo-Keto Reductases Proteins 0.000 claims 4
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical group CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 claims 4
- 229960003464 mefenamic acid Drugs 0.000 claims 4
- 102000004316 Oxidoreductases Human genes 0.000 claims 1
- 108090000854 Oxidoreductases Proteins 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 description 3
- 229940100197 antimetabolite Drugs 0.000 description 3
- 239000002256 antimetabolite Substances 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- -1 platinum Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009257281A JP5578498B2 (ja) | 2009-11-10 | 2009-11-10 | 抗癌剤キット及び抗癌剤効果増強剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009257281A JP5578498B2 (ja) | 2009-11-10 | 2009-11-10 | 抗癌剤キット及び抗癌剤効果増強剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011102255A JP2011102255A (ja) | 2011-05-26 |
| JP2011102255A5 true JP2011102255A5 (enExample) | 2013-01-17 |
| JP5578498B2 JP5578498B2 (ja) | 2014-08-27 |
Family
ID=44192766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009257281A Expired - Fee Related JP5578498B2 (ja) | 2009-11-10 | 2009-11-10 | 抗癌剤キット及び抗癌剤効果増強剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5578498B2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6516723B2 (ja) | 2014-02-20 | 2019-05-22 | 浩文 山本 | 抗癌剤の抗腫瘍効果の増強剤 |
| US10167293B2 (en) * | 2016-05-26 | 2019-01-01 | Bayer Pharma Aktiengesellschaft | [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanones |
| CN116064799B (zh) * | 2022-09-09 | 2025-10-28 | 上海长征医院 | Akr1c1在制备肝外胆管癌诊治产品中的应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2008012225A (es) * | 2006-03-23 | 2008-12-03 | Schering Corp | Combinaciones de inhibidores de proteasa de virus de hepatitis c e inhibidores de isoenzima 3a4 del citocromo p450, y metodos de tratamiento relacionados con las mismas. |
-
2009
- 2009-11-10 JP JP2009257281A patent/JP5578498B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Huff et al. | Inhibitors of the cancer target ribonucleotide reductase, past and present | |
| JP2010503695A5 (enExample) | ||
| NO20070155L (no) | 5-amino-2,4,7-triokso-3,4,7,8-tetrahydro-2H-pyrido[2,3-D]pyrimidinderivater og relaterte forbindelser for behandling av kreft | |
| JP2009531457A5 (enExample) | ||
| MY142067A (en) | Xanthine derivatives as selective hm74a agonists, processes for the manufacture of said derivatives, formulations comprising these derivatives, and their use in the treatment of diseases where under-activation of the hm74a receptor contributes to the disease | |
| MX2010014057A (es) | Compuestos de piridina. | |
| EP2348112A3 (en) | Stabilized immune modulatory RNA (SIMRA) compounds | |
| Achhra et al. | Antiretroviral regimens sparing agents from the nucleoside (tide) reverse transcriptase inhibitor class: a review of the recent literature | |
| CL2007003635A1 (es) | Compuestos derivados de 6-amino-purin-8-ona; proceso de preparacion; composicion farmaceutica; proceso para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades alergicas, virales o cancer. | |
| DE602006014579D1 (de) | Heteroalkylgebundene pyrimidinderivate | |
| JP2009513660A5 (enExample) | ||
| MY166288A (en) | Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt | |
| ATE474560T1 (de) | Pharmazeutische kombination aus nucleotid und nucleosid-reverse-transkriptase-hemmern (wie tenofovir und lamivudin) in verschiedenen teilen der dosiereinheit | |
| DE602008003404D1 (de) | 5,6,7,8-tetrahydropteridin-derivate als hsp90-hemmer | |
| Clarke et al. | Discovery of β-d-2′-deoxy-2′-α-fluoro-4′-α-cyano-5-aza-7, 9-dideaza adenosine as a potent nucleoside inhibitor of respiratory syncytial virus with excellent selectivity over mitochondrial RNA and DNA polymerases | |
| JP2009542581A5 (enExample) | ||
| IL192763A (en) | History of pyrimidine, preparations containing them and used in the preparation of cancer drugs | |
| Webster et al. | eFT508, a potent and selective mitogen-activated protein kinase interacting kinase (MNK) 1 and 2 inhibitor, is efficacious in preclinical models of diffuse large B-cell lymphoma (DLBCL) | |
| Gotlib et al. | KIT inhibitor midostaurin exhibits a high rate of clinically meaningful and durable responses in advanced systemic mastocytosis: report of a fully accrued phase II trial | |
| JP6990934B2 (ja) | 異所性脂肪蓄積治療用ａ３アデノシン受容体リガンド | |
| JP2016014051A5 (enExample) | ||
| HRP20161293T1 (hr) | Rnki-molekula za sintezu timidilata i njezina uporaba | |
| WO2007012479A3 (en) | Benzylpiperazine derivates and their medical use | |
| JP2014503589A5 (enExample) | ||
| JP2014185170A5 (enExample) |